The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.
Thiazide diuretic use may convey a decreased risk of fracture and as such, the protective effect of this class of medicine should be considered when prescribing thiazide diuretics in clinical practice.
Researchers sought to identify associations of female reproductive factors with incidence of total knee arthroplasty in osteoarthritis.
Anti-osteoporotic medications (mainly bisphosphonates) seem to equally prevent bone loss, especially in the lumbar spine, in patients with diabetes compared with patients without diabetes.
One reason selective serotonin reuptake inhibitors may affect the likelihood of osteoporosis is that the drug antagonizes the serotonin transporter, 5-HTT.
At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.
Intermittent use of high-dose glucocorticoids did not increase the risk for any, osteoporotic, hip, or clinically symptomatic vertebral fractures in patients with chronic obstructive pulmonary disease.
Researchers have determined that treatment for osteoporosis with teriparatide is associated with greater bone formation than treatment with zoledronic acid.
Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.
In this review, 2 independent investigators searched clinical trial databases for studies that evaluated the link between vitamin D supplements and bone health in adult patients with epilepsy.
Abatacept was superior at increasing bone mineral density in the femoral neck compared with other biologic disease-modifying antirheumatic drugs, and may offer good efficacy for improving BMD in rheumatoid arthritis.
Researchers showed that decreased L1 trabecular attenuation is associated with increased risk for future osteoporotic fractures in adult patients aged ≥65 years undergoing abdominopelvic CT scans for other indications.
Researchers compared the effects of combined metformin and COX-2 inhibitor therapy vs COX-2 therapy alone on joint replacement surgery rates.
Researchers observed detrimental effects of RYGB on bone turnover, mass, structure, and strength just 6 months postoperatively, and these effects persisted throughout the duration of the 12-month study.
The use of biologic disease-modifying antirheumatic drugs has no medium-term effect on the risk for spinal fractures among patients with ankylosing spondylitis.
Study assessed the effect of denosumab on bone mineral density and incident fractures in older adults with primary hyperparathyroidism who could not undergo or refused surgery.
Study showed that parathyroid hormone was a significant predictor of lumbar spine bone mineral density Z-score for pseudohypoparathyroidism 1B patients.
A lower bone mineral density in the lumbar spine, femoral neck, and hip is associated with an increased risk for intracranial aneurysm.
In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.
Increased odds of fractures in pediatric patients with asthma may be associated with systemic corticosteroid use, but not with inhaled corticosteroid use.
Study investigated the correlations between age and body composition with trabecular morphology in a cohort of healthy girls age 9 to 18.
A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
New findings do not support routine vitamin D and calcium supplementation in community-dwelling older adults for lowering the incidence of osteoporosis-related fractures.
Researchers conducted a long-term follow-up study to determine whether BMD loss, osteoporosis, and fractures were successfully treated or prevented in an urban population of patients with epilepsy and reduced bone density.
Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.
Bone mineral density was evaluated annually of the lumbar spine and femoral neck.
The association between alendronate use and nonvertebral fracture was strongest in patients who received high doses of glucocorticoid.
In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.
Endocrinology Advisor Articles
- Obesity Risk in Infants Born to Women With Diabetes
- Nivolumab Associated With Thyroiditis in Patients With Cancer
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Diabetes May Decrease Ability to Feel Acid Regurgitation
- April 28 Is Drug Take Back Day
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- ACP: Position Paper Recommends Solutions to Close Gender Equity Gap
- Vitamin D Insufficiency Associated With Insulin Resistance Independent of Obesity in Children
- Factors Identified to Predict Fatty Liver in Obese Teens